{"id":17031,"date":"2025-04-24T09:42:39","date_gmt":"2025-04-24T07:42:39","guid":{"rendered":"https:\/\/adntro.com\/?p=17031"},"modified":"2025-07-24T12:48:04","modified_gmt":"2025-07-24T10:48:04","slug":"lecanemab-perfil-genetico-apoe","status":"publish","type":"post","link":"https:\/\/adntro.com\/en\/blog\/pharmacogenetics-pharmacogenomics\/lecanemab-profile-genetic-apoe\/","title":{"rendered":"Alzheimer's Treatment with Lecanemab: Why your Genetic Profile (APOE) Matters"},"content":{"rendered":"<h2 class=\"wp-block-heading\">What is Alzheimer's disease and how does genetics (APOE) play a role?<\/h2>\n\n\n\n<p class=\" translation-block\"><strong>Alzheimer's <a href=\"https:\/\/adntro.com\/es\/blog\/salud\/alzheimer\/\" target=\"_blank\" rel=\"noreferrer noopener\">disease<\/a> is the most common form of <a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia\" target=\"_blank\" rel=\"noreferrer noopener\">dementia<\/a><\/strong>, responsible for between 60% and 80% of cases. It is considered a neurocognitive condition linked to aging, as its frequency increases markedly with age. In Western populations, it affects approximately <strong>1% of people aged 65<\/strong>, but impacts as many as one in four among those over 90. As the world's population ages, millions of people are facing, directly or indirectly, this diagnosis that impairs memory, reasoning, orientation and, over time, even the ability to perform basic day-to-day tasks.<\/p>\n\n\n\n<p>Although Alzheimer's disease is a complex disease influenced by multiple factors, one of the most important is <strong>most studied genetic elements is the gene <em>APOE<\/em><\/strong>. This gene has several common variants that can increase or decrease the risk of developing it. In particular, the<strong> people <\/strong>that inherit<strong> two copies<\/strong> of the variant <strong>APOE-\u03b54<\/strong> have a risk of between <strong>8 and 10 times greater<\/strong> of suffering from Alzheimer's compared to those who do not have it.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img fetchpriority=\"high\" decoding=\"async\" width=\"649\" height=\"648\" src=\"https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/Alzheimer_perfil_genetico_apoe_2.png\" alt=\"Lecanemab and APOE genetic profiling\" class=\"wp-image-17035\" style=\"width:413px;height:auto\" srcset=\"https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/Alzheimer_perfil_genetico_apoe_2.png 649w, https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/Alzheimer_perfil_genetico_apoe_2-300x300.png 300w, https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/Alzheimer_perfil_genetico_apoe_2-150x150.png 150w, https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/Alzheimer_perfil_genetico_apoe_2-12x12.png 12w\" sizes=\"(max-width: 649px) 100vw, 649px\" \/><\/figure>\n<\/div>\n\n\n<h2 class=\"wp-block-heading\">What is lecanemab and why is it important to know the genetic profile (APOE)?<\/h2>\n\n\n\n<p>The revolutionary <strong>drug lecanemab <\/strong>focuses on <strong>slowing cognitive decline in the early stages of Alzheimer's disease<\/strong>. This is a monoclonal antibody marketed as <strong><a href=\"https:\/\/www.leqembi.com\/es\" target=\"_blank\" rel=\"noreferrer noopener\">Leqembi<\/a><\/strong>. Its mission is to directly attack one of the causes of Alzheimer's disease: the <strong>accumulation <\/strong>of a protein called <strong>beta-amyloid<\/strong> in the brain. When this protein aggregates, it forms neuritic plaques associated with neuronal death and loss of cognitive function. Lecanemab binds to these aggregates and <strong>signals for the immune system to recognize and eliminate them.<\/strong>This helps to reduce the accumulation of <strong>beta-amyloid<\/strong> in the brain.<\/p>\n\n\n\n<p>This <strong>drug<\/strong> has been <strong>approved by the European Commission<\/strong>\u00a0(EC) on April 15th, 2025 to treat mild cognitive impairment in the early stages of Alzheimer's disease in the European Union. With the aim of reducing the drug's side effects, the drug has been approved<strong> for patients only <\/strong>with beta-amyloid plaques in the brain that only have <strong>one copy or none of ApoE4.<\/strong><\/p>\n\n\n\n<p>According to EMA, \"<strong>patients with only one copy or no copies of\u00a0<em>ApoE4<\/em>\u00a0are less likely to experience<\/strong> amyloid-related imaging abnormalities (ARIA) that individuals with two copies of\u00a0<em>ApoE4<\/em>. The ARIA is a <strong>serious side effect<\/strong> recognized with Leqembi involving swelling and possible hemorrhage in the brain.\"<\/p>\n\n\n\n<p>In addition to the strict conditions imposed by the European Commission, for the same reason the U.S. Food and Drug Administration (<strong>FDA<\/strong>), which approved the use of this drug in the US a year ago, <strong>recommends genetic testing for this variant before starting treatment.<\/strong><\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" width=\"648\" height=\"645\" src=\"https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/regulacion_lecanemab_2.png\" alt=\"Lecanemab approved\" class=\"wp-image-17037\" style=\"width:374px;height:auto\" srcset=\"https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/regulacion_lecanemab_2.png 648w, https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/regulacion_lecanemab_2-300x300.png 300w, https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/regulacion_lecanemab_2-150x150.png 150w, https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/regulacion_lecanemab_2-12x12.png 12w\" sizes=\"(max-width: 648px) 100vw, 648px\" \/><\/figure>\n<\/div>\n\n\n<h2 class=\"wp-block-heading\">How can I know my APOE genetic profile?<\/h2>\n\n\n\n<p>The gene configuration <strong><em>APOE<\/em><\/strong> is determined by the combination of two genetic variants. Thanks to advances in genetics, it is now possible to know this information quickly, easily and affordably using different technologies. Companies such as <strong><a href=\"https:\/\/adntro.com\/en\/\">ADNTRO<\/a> offer accessible genetic tests that can identify whether a person carries<\/strong> variants such as <strong><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/gene\/348\" target=\"_blank\" rel=\"noreferrer noopener\">APOE<\/a>-\u03b54<\/strong>The results of this study are key to assessing the risk of Alzheimer's disease and the suitability of treatments such as lecanemab.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What does the evidence say about the effect of Lecanemab?<\/h2>\n\n\n\n<p class=\" translation-block\">The most important <b>clinical trial<\/b> backing lecanemab is called <b>CLARITY<\/b>, a Phase 3 study with <b>1,800 participants affected<\/b> by mild cognitive impairment or in the mild stage of dementia as a result of Alzheimer's disease<\/p>\n\n\n\n<p>In that trial, patients were treated with lecanemab for 18 months and observed that <strong>the drug slowed cognitive decline by 27%<\/strong> compared to those who received placebo.<\/p>\n\n\n\n<p>As with any drug, lecanemab may present <strong>side effects<\/strong> such as dizziness, headache, vision changes, worsening confusion, brain swelling or bleeding, and brain shrinkage. For that reason, the European Commission has restricted the use of this drug to patients with none or one copy of the APOE-\u03b54 configuration. Excluding patients at increased risk of developing serious adverse effects.<\/p>","protected":false},"excerpt":{"rendered":"<p>What is Alzheimer's disease and how does genetics play a role (APOE)? Alzheimer's disease is the most common form of dementia, responsible for between 60% and 80% of cases. It is considered a neurocognitive condition linked to aging, as its frequency increases markedly with age. In Western populations, it affects approximately [...]<\/p>","protected":false},"author":8,"featured_media":17037,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[42,417,418,671,673,670,672,668,669,20],"class_list":["post-17031","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-farmacogenetica-farmacogenomica","tag-adntro","tag-alzheimer","tag-apoe","tag-ce","tag-e4","tag-ema","tag-fda","tag-lecanemab","tag-leqembi","tag-snp"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lecanemab y perfil gen\u00e9tico APOE<\/title>\n<meta name=\"description\" content=\"\u00bfLecanemab se puede usar en todos los pacientes de alzheimer? No, el perfil gen\u00e9tico (APOE) es clave para la administraci\u00f3n de lecanemab\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/adntro.com\/en\/blog\/pharmacogenetics-pharmacogenomics\/lecanemab-profile-genetic-apoe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lecanemab y perfil gen\u00e9tico APOE\" \/>\n<meta property=\"og:description\" content=\"\u00bfLecanemab se puede usar en todos los pacientes de alzheimer? No, el perfil gen\u00e9tico (APOE) es clave para la administraci\u00f3n de lecanemab\" \/>\n<meta property=\"og:url\" content=\"https:\/\/adntro.com\/en\/blog\/pharmacogenetics-pharmacogenomics\/lecanemab-profile-genetic-apoe\/\" \/>\n<meta property=\"og:site_name\" content=\"ADNTRO\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ADNTROSPAIN\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-24T07:42:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-24T10:48:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/regulacion_lecanemab_2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"648\" \/>\n\t<meta property=\"og:image:height\" content=\"645\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandra Ferreiro\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@adntrospain\" \/>\n<meta name=\"twitter:site\" content=\"@adntrospain\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandra Ferreiro\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/\"},\"author\":{\"name\":\"Sandra Ferreiro\",\"@id\":\"https:\/\/adntro.com\/de\/#\/schema\/person\/a71eca38b563da2bb60f24d7e71f7d6b\"},\"headline\":\"Tratamiento del Alzheimer con Lecanemab: por qu\u00e9 tu Perfil Gen\u00e9tico (APOE) importa\",\"datePublished\":\"2025-04-24T07:42:39+00:00\",\"dateModified\":\"2025-07-24T10:48:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/\"},\"wordCount\":741,\"publisher\":{\"@id\":\"https:\/\/adntro.com\/de\/#organization\"},\"keywords\":[\"adntro\",\"alzheimer\",\"APOE\",\"CE\",\"E4\",\"EMA\",\"FDA\",\"lecanemab\",\"leqembi\",\"SNP\"],\"articleSection\":[\"Farmacogen\u00e9tica y farmacogen\u00f3mica\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/\",\"url\":\"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/\",\"name\":\"Lecanemab y perfil gen\u00e9tico APOE\",\"isPartOf\":{\"@id\":\"https:\/\/adntro.com\/de\/#website\"},\"datePublished\":\"2025-04-24T07:42:39+00:00\",\"dateModified\":\"2025-07-24T10:48:04+00:00\",\"description\":\"\u00bfLecanemab se puede usar en todos los pacientes de alzheimer? No, el perfil gen\u00e9tico (APOE) es clave para la administraci\u00f3n de lecanemab\",\"breadcrumb\":{\"@id\":\"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/adntro.com\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tratamiento del Alzheimer con Lecanemab: por qu\u00e9 tu Perfil Gen\u00e9tico (APOE) importa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/adntro.com\/de\/#website\",\"url\":\"https:\/\/adntro.com\/de\/\",\"name\":\"ADNTRO\",\"description\":\"Gen\u00e9tica, salud, nutrici\u00f3n\",\"publisher\":{\"@id\":\"https:\/\/adntro.com\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/adntro.com\/de\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/adntro.com\/de\/#organization\",\"name\":\"ADNTRO Genetics\",\"url\":\"https:\/\/adntro.com\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/adntro.com\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/adntro.com\/wp-content\/uploads\/2021\/08\/android-chrome-512x512-2.png\",\"contentUrl\":\"https:\/\/adntro.com\/wp-content\/uploads\/2021\/08\/android-chrome-512x512-2.png\",\"width\":512,\"height\":512,\"caption\":\"ADNTRO Genetics\"},\"image\":{\"@id\":\"https:\/\/adntro.com\/de\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ADNTROSPAIN\/\",\"https:\/\/twitter.com\/adntrospain\",\"https:\/\/www.instagram.com\/adntro_\/\",\"https:\/\/www.pinterest.es\/ADNTRO_TEAM\/_saved\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/adntro.com\/de\/#\/schema\/person\/a71eca38b563da2bb60f24d7e71f7d6b\",\"name\":\"Sandra Ferreiro\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/adntro.com\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ddaa4448bc53192d65c596cd5119749fb4d7167a3b3d7931d8b0470a2021bdc3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ddaa4448bc53192d65c596cd5119749fb4d7167a3b3d7931d8b0470a2021bdc3?s=96&d=mm&r=g\",\"caption\":\"Sandra Ferreiro\"},\"description\":\"Bioinform\u00e1tica y Responsable del \u00e1rea cient\u00edfica en ADNTRO. Biotecn\u00f3loga por la Universidad Francisco de Vitoria, donde recibi\u00f3 dos becas de expediente acad\u00e9mico brillante. Estuvo trabajando en un proyecto de investigaci\u00f3n sobre la asimetr\u00eda izquierda-derecha en Newcastle, siendo premiada en la Conferencia del Centro de Investigaci\u00f3n Cardiovascular Trainees Meeting como el mejor p\u00f3ster (2018). Complet\u00f3 un m\u00e1ster en Biolog\u00eda Computacional en la Universidad Polit\u00e9cnica de Madrid. All\u00ed estudi\u00f3 las redes de interacci\u00f3n metab\u00f3lica en el microbioma de pacientes con Enfermedad de Chron y Colitis Ulcerosa en el centro de investigaci\u00f3n CBGP, centro de Excelencia Severo Ochoa (2020). Desde el 2020 es Bioinform\u00e1tica en ADNTRO donde desarrolla modelos predictivos, realiza anotaciones y an\u00e1lisis de variantes patog\u00e9nicas, investigaci\u00f3n de literatura GWAS y divulgaci\u00f3n cient\u00edfica.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/sandra-ferreiro-lpez-78804016a\/\"],\"url\":\"https:\/\/adntro.com\/en\/blog\/author\/sandra\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lecanemab y perfil gen\u00e9tico APOE","description":"\u00bfLecanemab se puede usar en todos los pacientes de alzheimer? No, el perfil gen\u00e9tico (APOE) es clave para la administraci\u00f3n de lecanemab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/adntro.com\/en\/blog\/pharmacogenetics-pharmacogenomics\/lecanemab-profile-genetic-apoe\/","og_locale":"en_US","og_type":"article","og_title":"Lecanemab y perfil gen\u00e9tico APOE","og_description":"\u00bfLecanemab se puede usar en todos los pacientes de alzheimer? No, el perfil gen\u00e9tico (APOE) es clave para la administraci\u00f3n de lecanemab","og_url":"https:\/\/adntro.com\/en\/blog\/pharmacogenetics-pharmacogenomics\/lecanemab-profile-genetic-apoe\/","og_site_name":"ADNTRO","article_publisher":"https:\/\/www.facebook.com\/ADNTROSPAIN\/","article_published_time":"2025-04-24T07:42:39+00:00","article_modified_time":"2025-07-24T10:48:04+00:00","og_image":[{"width":648,"height":645,"url":"https:\/\/adntro.com\/wp-content\/uploads\/2025\/04\/regulacion_lecanemab_2.png","type":"image\/png"}],"author":"Sandra Ferreiro","twitter_card":"summary_large_image","twitter_creator":"@adntrospain","twitter_site":"@adntrospain","twitter_misc":{"Written by":"Sandra Ferreiro","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/#article","isPartOf":{"@id":"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/"},"author":{"name":"Sandra Ferreiro","@id":"https:\/\/adntro.com\/de\/#\/schema\/person\/a71eca38b563da2bb60f24d7e71f7d6b"},"headline":"Tratamiento del Alzheimer con Lecanemab: por qu\u00e9 tu Perfil Gen\u00e9tico (APOE) importa","datePublished":"2025-04-24T07:42:39+00:00","dateModified":"2025-07-24T10:48:04+00:00","mainEntityOfPage":{"@id":"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/"},"wordCount":741,"publisher":{"@id":"https:\/\/adntro.com\/de\/#organization"},"keywords":["adntro","alzheimer","APOE","CE","E4","EMA","FDA","lecanemab","leqembi","SNP"],"articleSection":["Farmacogen\u00e9tica y farmacogen\u00f3mica"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/","url":"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/","name":"Lecanemab y perfil gen\u00e9tico APOE","isPartOf":{"@id":"https:\/\/adntro.com\/de\/#website"},"datePublished":"2025-04-24T07:42:39+00:00","dateModified":"2025-07-24T10:48:04+00:00","description":"\u00bfLecanemab se puede usar en todos los pacientes de alzheimer? No, el perfil gen\u00e9tico (APOE) es clave para la administraci\u00f3n de lecanemab","breadcrumb":{"@id":"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/adntro.com\/es\/blog\/farmacogenetica-farmacogenomica\/lecanemab-perfil-genetico-apoe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/adntro.com\/es\/"},{"@type":"ListItem","position":2,"name":"Tratamiento del Alzheimer con Lecanemab: por qu\u00e9 tu Perfil Gen\u00e9tico (APOE) importa"}]},{"@type":"WebSite","@id":"https:\/\/adntro.com\/de\/#website","url":"https:\/\/adntro.com\/de\/","name":"ADNTRO","description":"Gen\u00e9tica, salud, nutrici\u00f3n","publisher":{"@id":"https:\/\/adntro.com\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/adntro.com\/de\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/adntro.com\/de\/#organization","name":"ADNTRO Genetics","url":"https:\/\/adntro.com\/de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/adntro.com\/de\/#\/schema\/logo\/image\/","url":"https:\/\/adntro.com\/wp-content\/uploads\/2021\/08\/android-chrome-512x512-2.png","contentUrl":"https:\/\/adntro.com\/wp-content\/uploads\/2021\/08\/android-chrome-512x512-2.png","width":512,"height":512,"caption":"ADNTRO Genetics"},"image":{"@id":"https:\/\/adntro.com\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ADNTROSPAIN\/","https:\/\/twitter.com\/adntrospain","https:\/\/www.instagram.com\/adntro_\/","https:\/\/www.pinterest.es\/ADNTRO_TEAM\/_saved\/"]},{"@type":"Person","@id":"https:\/\/adntro.com\/de\/#\/schema\/person\/a71eca38b563da2bb60f24d7e71f7d6b","name":"Sandra Ferreiro","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/adntro.com\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ddaa4448bc53192d65c596cd5119749fb4d7167a3b3d7931d8b0470a2021bdc3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ddaa4448bc53192d65c596cd5119749fb4d7167a3b3d7931d8b0470a2021bdc3?s=96&d=mm&r=g","caption":"Sandra Ferreiro"},"description":"Bioinform\u00e1tica y Responsable del \u00e1rea cient\u00edfica en ADNTRO. Biotecn\u00f3loga por la Universidad Francisco de Vitoria, donde recibi\u00f3 dos becas de expediente acad\u00e9mico brillante. Estuvo trabajando en un proyecto de investigaci\u00f3n sobre la asimetr\u00eda izquierda-derecha en Newcastle, siendo premiada en la Conferencia del Centro de Investigaci\u00f3n Cardiovascular Trainees Meeting como el mejor p\u00f3ster (2018). Complet\u00f3 un m\u00e1ster en Biolog\u00eda Computacional en la Universidad Polit\u00e9cnica de Madrid. All\u00ed estudi\u00f3 las redes de interacci\u00f3n metab\u00f3lica en el microbioma de pacientes con Enfermedad de Chron y Colitis Ulcerosa en el centro de investigaci\u00f3n CBGP, centro de Excelencia Severo Ochoa (2020). Desde el 2020 es Bioinform\u00e1tica en ADNTRO donde desarrolla modelos predictivos, realiza anotaciones y an\u00e1lisis de variantes patog\u00e9nicas, investigaci\u00f3n de literatura GWAS y divulgaci\u00f3n cient\u00edfica.","sameAs":["https:\/\/www.linkedin.com\/in\/sandra-ferreiro-lpez-78804016a\/"],"url":"https:\/\/adntro.com\/en\/blog\/author\/sandra\/"}]}},"_links":{"self":[{"href":"https:\/\/adntro.com\/en\/wp-json\/wp\/v2\/posts\/17031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/adntro.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/adntro.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/adntro.com\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/adntro.com\/en\/wp-json\/wp\/v2\/comments?post=17031"}],"version-history":[{"count":6,"href":"https:\/\/adntro.com\/en\/wp-json\/wp\/v2\/posts\/17031\/revisions"}],"predecessor-version":[{"id":17041,"href":"https:\/\/adntro.com\/en\/wp-json\/wp\/v2\/posts\/17031\/revisions\/17041"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/adntro.com\/en\/wp-json\/wp\/v2\/media\/17037"}],"wp:attachment":[{"href":"https:\/\/adntro.com\/en\/wp-json\/wp\/v2\/media?parent=17031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/adntro.com\/en\/wp-json\/wp\/v2\/categories?post=17031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/adntro.com\/en\/wp-json\/wp\/v2\/tags?post=17031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}